Jack Weinstein serves as chief executive officer. He brings over 40 years of executive management expertise in investment banking and consulting in the biopharmaceutical and life sciences industries. Jack has extensive experience in corporate finance, business development as well as FDA regulatory and intellectual property strategies.

Paolo Galfetti is Chief Operating Officer. He has over 20 years of management experience in the pharmaceutical sector, including in the areas of business development and licensing, operational strategic management, clinical research, and pharmaceutical discovery and development. 

Christopher Wick is Relief Therapeutics’ U.S. Country Lead and is responsible for leading company’s U.S. commercial and sales teams. Prior to joining Relief, Christopher held positions in sales of increasing responsibility at Alexion Pharmaceuticals, Inc., GlaxoSmithKline and Novartis. where he developed and led high-performing, excellence award-winning teams and achieved best-in-the-nation sales for two rare disease products and consistently received top sales rankings.

Marco Marotta serves as Chief Business Officer. He brings deep, international expertise in operations, sales and business development within the pharmaceutical sector.

Jeremy Meinen serves as chief financial officer and treasurer. Prior to joining Relief, Jeremy provided financial consulting and controlling services to companies in various industries. Jeremy is a Swiss certified public accountant.

Serene Forte, Ph.D., MPH, is an accomplished scientific and clinical based leader with more than 20 years of direct leadership experience and a record of success blending scientific education and business acumen to drive business development, commercial strategy and medical affairs. Dr. Forte has extensive experience in the field of genetic medicines with direct involvement in the strategic launch development for several gene therapy companies. Most recently her focus has been on business development of genetic medicine assets. Her interests include rare disease, gene replacement, genetic medicines for neuromuscular and metabolic diseases, AAV technologies and gene editing.

Drew serves as Executive Director and Head of U.S. Marketing. She is proven leader, with a successful track record of launching numerous products in the rare disease space, and has deep expertise in digital technology, strategic planning and team building.

Raghuram (Ram) Selvaraju, Ph.D., MBA, is a Managing Director and Senior Healthcare Analyst in the Equity Research Division of H.C. Wainwright & Co., a New York-based full-service investment bank heavily focused on the healthcare sector. He has over 15 years of experience on Wall Street and previously was a pharmaceutical researcher at Serono in Switzerland. He holds Ph.D. and M.S. degrees from the University of Geneva and an M.B.A. from Cornell University.

Paolo Galfetti is Chief Operating Officer. He has over 20 years of management experience in the pharmaceutical sector, including in the areas of business development and licensing, operational strategic management, clinical research, and pharmaceutical discovery and development.

Patrice Jean is the Chair of the Life Sciences Practice at Hughes Hubbard & Reed, an international law firm based in New York City. She has over a decade of experience counselling leading and startup pharmaceutical, chemical and biotechnology companies in all areas of patent law, including asserting and defending patent rights underlying core technologies and innovations.

Tom Plitz recently served as Chief Executive Officer of Chord Therapeutics SA, a privately held biopharmaceutical firm based in Geneva, Switzerland, which was acquired by Merck KGaA in January 2022. He has more than two decades of R&D experience from senior management positions in the pharmaceutical industry.

Michelle Lock is the Chief Operating Officer of Covis Pharma Group, a global specialty pharmaceutical company based in Zug, Switzerland. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience.